Morepen Laboratories profit jumps 69% as CDMO production kicks off
The company reported a net profit of ₹20 crore for Q4 FY26, supported by a 31% expansion in its medical devices division and new manufacturing output.
— 2 earlier stories on Morepen Laboratories Ltd. →What's new
- Net profit rose 69% to ₹20 crore on a 22% increase in gross revenue to ₹472 crore.
- Medical devices business expanded by 31% during the quarter.
- Commercial production started for the ₹825 crore global CDMO mandate.
Why this matters
The start of commercial production for the CDMO mandate confirms that the company is moving from contract signing to revenue generation. This transition is critical for validating the firm's long-term manufacturing strategy.
What we're watching
- The pace of phased supply deliveries under the CDMO contract.
- Margin sustainability as the medical devices segment continues to scale.
- Updates on capacity expansion and USFDA-related developments.
The full read
Morepen Laboratories posted a net profit of ₹20 crore for the quarter ended March 2026, a 69% increase over the previous year. Gross revenue climbed 22% to ₹472 crore, aided by a 31% expansion in the medical devices business and steady export performance.
Production has finally started.
Beyond the financials, the company confirmed it has moved into commercial production for its ₹825 crore CDMO mandate, completing validation batches and aligning supply schedules for phased delivery. While these results align with trends established in earlier disclosures, the shift from contract validation to active production is a tangible step forward for the bottom line. The company's ability to maintain this momentum in its CDMO and medical devices segments remains the primary test for the coming quarters.
Questions answered
- What drove the 69% increase in net profit?
- Profit growth was fueled by strong export momentum and a 31% expansion in the company's medical devices business.
- What is the status of the ₹825 crore CDMO mandate?
- Morepen has commenced commercial production for the mandate. Validation batches are complete, and the company has aligned its supply schedules for phased delivery.
- How did top-line growth perform in Q4?
- Gross revenue for the quarter reached ₹472 crore, representing a 22% increase compared to the same period last year.
- Is this a new development for the company?
- The financial results and the CDMO order were largely anticipated by the market based on prior disclosures. The current update confirms the transition into the commercial production phase.
Story so far
All notes on MOREPENLAB →- 27 May 2026 · 8:26 AM IST Morepen Laboratories profit jumps 69% as CDMO production kicks off
- today Morepen Laboratories profit drops 20% as margins tighten
- 6d ago Morepen locks in medical devices chief with subsidiary shares